• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Infect Dis . Early Mortality After the First Dose of Coronavirus Disease 2019 Vaccination: A Target Trial Emulation

tetano

Editor, Senior Moderator
Clin Infect Dis


. 2024 Feb 6:ciad604.
doi: 10.1093/cid/ciad604. Online ahead of print. Early Mortality After the First Dose of Coronavirus Disease 2019 Vaccination: A Target Trial Emulation

Kevin W McConeghy[SUP] 1 2 [/SUP], Kwan Hur[SUP] 3 [/SUP], Issa J Dahabreh[SUP] 4 5 6 [/SUP], Rong Jiang[SUP] 3 [/SUP], Lucy Pandey[SUP] 3 [/SUP], Walid F Gellad[SUP] 7 8 9 [/SUP], Peter Glassman[SUP] 10 11 12 [/SUP], Chester B Good[SUP] 3 8 9 [/SUP], Donald R Miller[SUP] 3 13 [/SUP], Andrew R Zullo[SUP] 1 14 [/SUP], Stefan Gravenstein[SUP] 1 2 15 [/SUP], Francesca Cunningham[SUP] 3 [/SUP]



Affiliations
Abstract

Background: Vaccine hesitancy persists alongside concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines. We aimed to examine the effect of COVID-19 vaccination on risk of death among US veterans.
Methods: We conducted a target trial emulation to estimate and compare risk of death up to 60 days under two COVID-19 vaccination strategies: vaccination within 7 days of enrollment versus no vaccination through follow-up. The study cohort included individuals aged ≥18 years enrolled in the Veterans Health Administration system and eligible to receive a COVID-19 vaccination according to guideline recommendations from 1 March 2021 through 1 July 2021. The outcomes of interest included deaths from any cause and excluding a COVID-19 diagnosis. Observations were cloned to both treatment strategies, censored, and weighted to estimate per-protocol effects.
Results: We included 3 158 507 veterans. Under the vaccination strategy, 364 993 received vaccine within 7 days. At 60 days, there were 156 deaths per 100 000 veterans under the vaccination strategy versus 185 deaths under the no vaccination strategy, corresponding to an absolute risk difference of -25.9 (95% confidence limit [CL], -59.5 to 2.7) and relative risk of 0.86 (95% CL, .7 to 1.0). When those with a COVID-19 infection in the first 60 days were censored, the absolute risk difference was -20.6 (95% CL, -53.4 to 16.0) with a relative risk of 0.88 (95% CL, .7 to 1.1).
Conclusions: Vaccination against COVID-19 was associated with a lower but not statistically significantly different risk of death in the first 60 days. These results agree with prior scientific knowledge suggesting vaccination is safe with the potential for substantial health benefits.

Keywords: COVID-19 vaccination; Risk of death; SARS-CoV-2; medication safety; vaccine safety.

 
Back
Top Bottom